Ionis Pharmaceuticals, Inc.
MODIFIED COMPOUNDS AND USES THEREOF

Last updated:

Abstract:

The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications. In certain embodiments, the present disclosure provides oligomeric compounds having an improved therapeutic index or an increased maximum tolerated dose.

Status:
Application
Type:

Utility

Filling date:

12 Feb 2019

Issue date:

21 Jan 2021